Radioiodine Therapy After Pretreatment With Recombinant Thyroid-stimulating Hormone (tsh) in Toxic Multinodular Goiter With Low Radioactive Iodine Uptake
{"title":"Radioiodine Therapy After Pretreatment With Recombinant Thyroid-stimulating Hormone (tsh) in Toxic Multinodular Goiter With Low Radioactive Iodine Uptake","authors":"H. Padmanabhan","doi":"10.1097/TEN.0B013E3181E94ABF","DOIUrl":null,"url":null,"abstract":"Abstract: Managing toxic multinodular goiter in elderly patients can be challenging as age, presence of chronic disease, polypharmacy, and poor medication compliance can limit the use of surgery and long-term antithyroid drugs. Treatment with 131I may not produce the best outcome in states of low radioiodine uptake. Recombinant human thyroid-stimulating hormone (rh-TSH, Thyrogen) used as pretreatment for radioiodine therapy, however, can be useful in this clinical scenario. We report a patient successfully treated (a 94-year-old man on polypharmacy for multiple medical conditions) with radioiodine after pretreatment with rh-TSH. The radioiodine uptake increased with rh-TSH administration and allowed successful treatment with 15.4 mCu of 131I. Recovery from hyperthyroidism was associated with a 71% reduction in the size of thyroid gland by sonography.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"2 1","pages":"208-210"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TEN.0B013E3181E94ABF","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Managing toxic multinodular goiter in elderly patients can be challenging as age, presence of chronic disease, polypharmacy, and poor medication compliance can limit the use of surgery and long-term antithyroid drugs. Treatment with 131I may not produce the best outcome in states of low radioiodine uptake. Recombinant human thyroid-stimulating hormone (rh-TSH, Thyrogen) used as pretreatment for radioiodine therapy, however, can be useful in this clinical scenario. We report a patient successfully treated (a 94-year-old man on polypharmacy for multiple medical conditions) with radioiodine after pretreatment with rh-TSH. The radioiodine uptake increased with rh-TSH administration and allowed successful treatment with 15.4 mCu of 131I. Recovery from hyperthyroidism was associated with a 71% reduction in the size of thyroid gland by sonography.